In one embodiment, the present application discloses mixtures comprising (a) water in an amount of at least 1% wt/wt of the mixture; (b) a transition metal catalyst; and (c) one or more solubilizing agents; and methods for using such mixtures for performing transition metal mediated bond formation reactions.

In one embodiment, the present application discloses mixtures comprising (a) water in an amount of at least 1% wt/wt of the mixture; (b) a transition metal catalyst; and (c) one or more solubilizing agents; and methods for using such mixtures for performing transition metal mediated bond formation reactions.

In one embodiment, the present application discloses mixtures comprising (a) water in an amount of at least 1% wt/wt of the mixture; (b) a transition metal catalyst; and (c) one or more solubilizing agents; and methods for using such mixtures for performing transition metal mediated bond formation reactions.

The disclosure provides Group 6 complexes, which, in some embodiments, are useful for catalyzing olefin metathesis reactions. In some embodiments, the compounds are compounds of the following formula (I) wherein: M is a Group 6 metal atom; X is an oxygen atom, NR.sup.5, NN(R.sup.5)(R.sup.5) or NOR.sup.5, R.sup.5 and R.sup.5 independently being various substituents, such as aryl or heteroaryl, each optionally substituted; n is 0 or 1; R.sup.z is a neutral ligand; R.sup.1 is hydrogen or an organic substituent; R.sup.2 is an aryl or heteroaryl group, each optionally substituted; R.sup.3 is an anionic ligand; and R.sup.4 is an anionic ligand, such as a pyrrolide, a pyrazolide, an imidazolide, an indolide, an azaindolide, or an indazolide, each optionally substituted.

##STR00001##

The disclosure provides Group 6 complexes, which, in some embodiments, are useful for catalyzing olefin metathesis reactions. In some embodiments, the compounds are compounds of the following formula (I) wherein: M is a Group 6 metal atom; X is an oxygen atom, NR.sup.5, NN(R.sup.5)(R.sup.5) or NOR.sup.5, R.sup.5 and R.sup.5 independently being various substituents, such as aryl or heteroaryl, each optionally substituted; n is 0 or 1; R.sup.z is a neutral ligand; R.sup.1 is hydrogen or an organic substituent; R.sup.2 is an aryl or heteroaryl group, each optionally substituted; R.sup.3 is an anionic ligand; and R.sup.4 is an anionic ligand, such as a pyrrolide, a pyrazolide, an imidazolide, an indolide, an azaindolide, or an indazolide, each optionally substituted.

##STR00001##

A series of sofalcone derivatives having the effect of inhibiting platelet aggregation and antithrombotic effect are disclosed. These sofalcone derivatives are antagonists of TxA2 receptor and have the effect of inhibiting platelet activation and aggregation without causing bleeding. In addition, a preparing method of the sofalcone derivatives and a method for preventing or treating thrombotic diseases or inhibiting platelet aggregation by administrating the sofalcone derivatives are also disclosed.

A series of sofalcone derivatives having the effect of inhibiting platelet aggregation and antithrombotic effect are disclosed. These sofalcone derivatives are antagonists of TxA2 receptor and have the effect of inhibiting platelet activation and aggregation without causing bleeding. In addition, a preparing method of the sofalcone derivatives and a method for preventing or treating thrombotic diseases or inhibiting platelet aggregation by administrating the sofalcone derivatives are also disclosed.

A method for the synthesis of multilayer -graphyne, an intrinsically semi-conducting sp.sup.2/sp.sup.1 allotrope of carbon, through crystallization-assisted irreversible cross-coupling polymerization.

A method for the synthesis of multilayer -graphyne, an intrinsically semi-conducting sp.sup.2/sp.sup.1 allotrope of carbon, through crystallization-assisted irreversible cross-coupling polymerization.